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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2015, TaiwanAbstract This study was performed to elucidate the potential of human platelet lysate
(huPL) as an alternative to xeno-free media for culturing mesenchymal stem cells (MSCs). In
this work, Wharton’s jelly-derived MSCs (WJ-MSCs; n Z 5) were isolated, characterized, and
cultured in huPL derived from type O platelets reconstituted with type AB platelet-poor
plasma (huPLeABO). WJ-MSCs from five donors were cultured under two different conditions
[cell culture supplemented with 20% fetal bovine serum (FBS) and 0.250 mg/mL, 0.125 mg/
mL, 0.063 mg/mL, and 0.031 mg/mL huPL]. Growth kinetics, cell surface markers, and
in vitro differentiation potential toward the adipogenic, chondrogenic, and osteogenic line-
ages were evaluated. Our results indicate that WJ-MSCs cultured in the presence of huPLeABO
showed typical fibroblast-like morphology and had a significantly higher cell count (p < 0.05),
compared with those cultured in FBS. Furthermore, results of immunophenotyping assay
showed similar MSCs characteristics for both culture conditions. In addition, no significant dif-
ferences were observed in the MSCs differentiation toward the adipogenic, chondrogenic, and
osteogenic lineages. The optimal concentrations of huPLeABO in the culture medium were
0.250 mg/mL and 0.125 mg/mL. Because of insignificant differences between the concentra-
tions in terms of WJ-MSCs population doubling time, the concentration of 0.125 mg/mL was
used in all comparisons between FBS and huPLeABO. The average concentrations of insulin-
like growth factor-1, platelet-derived growth factor-AB, vascular endothelial growth factor,
and transforming growth factor-b1 in huPLeABO were 287.89 pg/mg, 47,096.63 pg/mg,earch Center, Faculty of Medicine, Maranatha Christian University, Jalan Professor Dokter Gigi Surya
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88 A.A. Antoninus et al.150.93 pg/mg, and 74,817.76 pg/mg, respectively. huPLeABO produced by this method was
able to enhance the WJ-MSCs proliferation rate constantly and decrease the required time
to reach confluence compared with the FBS culture condition.
Copyright ª 2015, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
Mesenchymal stem cells (MSCs) have been a popular tool for
therapeutic application due to their multipotent differen-
tiation capacity and immunomodulatory characteristics.1
Although the bone marrow is an extensively studied
source of MSCs, the amount of bone-marrow-derived MSCs
is very limited and involves an invasive harvesting proce-
dure.2 Human umbilical cord contains an extra-embryonic
membrane with a rich source of MSCs called “Wharton’s
jelly.” Wharton’s jelly-derived MSCs (WJ-MSCs) are believed
to be more primitive than MSCs derived from other tissue
sources.3 WJ-MSCs have the unique properties of high pro-
liferation rates, wide multipotency, and hypo-
immunogenicity, as well as anticancer properties.
Moreover, WJ-MSCs expressed low levels of pluripotent
embryonic stem cell markers including POUF1, NANOG,
SOX2, and LIN28, which explains why they do not induce
teratomas.4e8 Most isolation and expansion protocols for
clinical-scale production of MSCs use culture media sup-
plemented with fetal bovine serum (FBS); however, MSCs
cultured in FBS might pose an infection risk, which can
cause immunological reactions in the host.9 Thus, there is a
significant safety concern when administering MSCs
cultured in FBS. It has also been reported that patients who
have received cell transplantation with MSCs expanded in
FBS exhibit antibodies against bovine antigens.10 Further-
more, different batches of FBS give variable efficiencies of
MSCs expansion in vitro.11
Human platelet lysate (huPL) is another culture medium
supplement, which can be a potential substitute for FBS for
culturing MSCs.12 huPL contains various growth factors such
as platelet-derived growth factor (PDGF), transforming
growth factor (TGF), and epidermal growth factor that
promote migration and proliferation of MSCs.13e18 Although
several studies were carried out on huPL, conflicting results
were obtained. For example, in one study an increase in
proliferation rate with huPL was reported, whereas in some
others huPL inhibited cell proliferation.13 huPL was re-
ported to induce cell differentiation in some studies,
whereas some studies reported that it did not exhibit any
cell differentiation properties.14 These differences could
be the result of different preparation methods of huPL
between studies and variability of growth factors concen-
tration between donors. Many extensive studies have been
carried out in this regard, but creating a standardized huPL
protocol for culturing MSCs remains a challenging task.19e21
Therefore, it is very important to establish a method to
produce huPL with a reproducible concentration of growth
factors and reliable effectiveness to expand MSCs in vitro
for clinical application. It has been reported that a mixtureof type O platelets and type AB plasma (huPLeABO) does
not induce possible influences of ABH antigens and
isoagglutinins.22
In this study, we established a standardized method for
producing huPLeABO for WJ-MSCs expansion that is
completely xeno free and comparable with culturing WJ-
MSCs in FBS in terms of cell proliferation, phenotype
characterization, and differentiation capacities. We also
measured the concentration of growth factors in huPL from
three batches.
Material and methods
Isolation, activation, and quantification of platelets
Seven samples of type O blood and two samples of type AB
blood were collected in a 250-mL blood bag with citrate
phosphate dextrose as anticoagulant (Terumo, Terumo
Medical Corporation, Shibuya, Japan). The freshly collected
blood samples were centrifuged (1000 g, 5 min) to separate
red blood cells from the rest of blood components. The
upper fraction was collected and centrifuged to separate
platelets from plasma. The collected type O platelets were
then reconstituted with type AB platelet-poor plasma.
Platelet-rich plasma (PRP) was activated through repeated
freezeethaw cycles, and the platelet lysate produced by
these methods was centrifuged to separate it from other
debris. The supernatant was collected for the quantifica-
tion of protein using NanoDrop 2000c (Thermo Fisher Sci-
entific Inc., Waltham, MA, USA) and for the quantification
of insulin-like growth factor-1 (IGF-1), PDGF-AB, vascular
endothelial growth factor (VEGF), and TGF-b1 concentra-
tion using Quantikine enzyme-linked immunosorbent assay
(ELISA) kit (R&D Systems Inc, Minneapolis, MN, USA) ac-
cording to the manufacturer’s protocols. The remaining
platelet lysates from donors were stored at 20C until
further use for cell culture medium supplementation.22
Isolation and culture of WJ-MSCs
Fresh human umbilical cords (n Z 5) were obtained after
full-term births (caesarian section) with informed consent,
according to the guidelines approved by the Ethics Com-
mittee at the Stem Cell and Cancer Institute (Jakarta,
Indonesia) and by the Ethics Committee collaboration be-
tween Maranatha Christian University (Bandung, Indonesia)
and Immanuel Hospital (Bandung, Indonesia). After rinsing
in normal saline (0.9% w/v sodium chloride), Wharton’s
jelly tissue was cut into small pieces (approximately
1e2 mm), and these were then placed in a tissue culture
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medium (MEM) alpha with 2mM GlutaMAX (Invitrogen,
Carlsbad, CA, USA), supplemented with 20% FBS (Invi-
trogen) or 0.03e0.250 mg/mL huPLeABO, and 100 U/mL
penicilline100 mg/mL streptomycin/amphotericin B (Invi-
trogen). Cultures were maintained in a humidified atmo-
sphere with 5% CO2 at 37
C. Approximately 3 weeks after
cultivation, the adherent cells and tissue fragments were
detached using trypsineEDTA solution (TrypLE Express,
Invitrogen) followed by inactivation with a basal medium.
The cells were harvested and replanted at 8  103 cells/
cm2.23,24
Growth factors assay of huPL
Assays of IGF-1, PDGF-AB, VEGF, and TGF-b1 were per-
formed to measure the concentration of these growth
factors in huPL from three batches of seven samples of type
O blood and two samples of type AB blood. The concen-
tration of growth factors was measured using the ELISA kit.
The IGF-1 assay was performed using Quantikine ELISA
human IGF-I immunoassay kit (R&D Systems). The PDGF-AB
assay was performed using Quantikine human PDGF-AB
immunoassay kit (R&D Systems). The VEGF assay was car-
ried out using Quantikine human VEGF immunoassay kit
(R&D Systems). The TGF-b1 assay was performed using
human TGF-1 immunoassay kit (R&D Systems).
Proliferation kinetics
WJ-MSCs were plated at 8  103 cells/cm2 in tissue culture
dishes and expanded using two different supplements,
namely, (1) 20% FBS and (2) 0.031 mg/mL, 0.063 mg/mL,
0.125 mg/mL, and 0.250 mg/mL of huPLeABO. Cells were
counted and passaged at a confluence of 80%. At each
passage, the population doubling (PD) was determined
using the following formula:
PD Z [log10[NH] e log10[NI]]/log10
where NI is the cell number of the inoculum and NH is the
cell harvest number.
The PD for each passage was calculated and added to
the PD of the previous passages to generate cumulative PD
data. The PD time (PDT) was obtained using the following
formula:
PDT Z t/PD (hours)
where t is the culture time (hours).
At the same time, a growth curve of WJ-MSCs from the
two different conditions was plotted against time. A total
of 200 cells/cm2 were seeded in six-well plates. On Day 3,
Day 5, Day 7, and Day 9, cells from one well were harvested
and counted.23
Immunophenotyping
For P4 and P8, WJ-MSCs cultured in 0.125 mg/mL
huPLeABO and 20% FBS were stained with antihuman an-
tibodies, which mark the following cell surface markers:CD105-PE, CD19-PE, HLADR-PE, CD14-FITC (Abcam, Cam-
bridge, UK), CD73-PE, CD34-FITC, and CD45-FITC (BD
Pharmingen, Franklin Lakes, NJ, USA). Cells incubated with
identical concentrations of fluorescein isothiocyanate- or
phycoerythrin-conjugated mouse immunoglobulin G isotype
antibodies (BD Pharmingen) served as negative controls.
The cells were analyzed by flow cytometry with a FACS-
Calibur 3 argon laser 488 nm (Becton Dickinson, Franklin
Lakes, NJ, USA) using CellQuest Pro Acquisition on the BD
FACStation Software (BD Biosciences). The experiments
and measurement of surface marker were performed in
triplicate.23,24
Differentiation of WJ-MSCs
Multipotency was confirmed by the ability of WJ-MSCs to
differentiate into adipocytes, chondrocytes, and osteo-
cytes. WJ-MSCs (P4 and P8) were plated in six-well plates at
1  104 cells/cm2 and incubated in the MSCs growth me-
dium in a humidified atmosphere with 5% CO2 at 37
C for 4
days.
For osteogenic differentiation, WJMSCs (P4 and P8) were
seeded at a density of 1  104 cells/cm2 in culture dishes
using the StemPro osteogenesis differentiation kit (Gibco
A10072-01, Invitrogen) for 3 weeks. Calcium deposits were
visualized using alizarin red S (Amresco 9436; AMRESCO
LLC, Solon, OH, USA). For chondrogenic differentiation,
WJMSCs were seeded at a density 1  104 cells/cm2 in
culture dishes using StemPro chondrogenesis differentia-
tion kit (Gibco A10071-01, Invitrogen) for 2 weeks. Chon-
drocytes were visualized using alcian blue (Amresco 0298).
Adipogenic differentiation of WJMSCs was performed using
the StemPro adipogenesis differentiation kit (Gibco A10070-
01, Invitrogen) for 2 weeks. We used oil red O (Sigma-
Aldrich-U0625) to confirm lipid droplets.24e27
Statistical analysis
Data were presented as means  standard deviation. Sta-
tistical comparisons were performed using one-way analysis
of variance. All p values < 0.05 were considered statisti-
cally significant.
Results
Growth factors concentration of huPLeABO
The concentration of growth factor (pg/mg) was calculated
by dividing the concentration of growth factors in
huPLeABO (pg/mL) with the total protein concentration
(mg/mL; Tables 1 and 2).
Immunophenotypic characterization of WJ-MSCs
WJ-MSCs at the early and late passages (P4 and P8) were
characterized by flow cytometry. A panel of seven markers
including CD105, CD73, CD14, CD19, CD34, CD45, and HLA-II
was tested. All WJ-MSCs cultured in MEM alpha and sup-
plemented with 0.25 mg/mL huPLeABO and 20% FBS were
negative for lymphocyte marker CD19, hematopoietic
Table 1 Growth factors concentration (pg/mL) of huPL-ABO from three batches.
Growth factors Concentration (pg/mL)
Batch I Batch II Batch III Average
IGF-1 1247.53 1435.78 1115.98 1266.43 160.73
PDGF-AB 235,140.79 193.220.56 196,408.45 208,256 23,336.89
VEGF 726.54 533,46 735.38 665.13 114.11
TGF-b1 319,500 286,000 378,300 327,933.33 46.724.33
huPL Z human platelet lysate; IGF-1 Z insulin-like growth factor-1; PDGF Z platelet-derived growth factor; TGF-b1 Z transforming
growth factor-b1; VEGF Z vascular endothelial growth factor.
Table 2 Growth factors concentration (pg/mg protein) of huPL-ABO from three batches.
Growth factors Concentration (pg/mg protein)
Batch I Batch II Batch III Average
Protein (mg/mL) 4.85 4.27 4.18 4.42 0.38
IGF-1 257.22 336.25 270.21 287.89 42.38
PDGF-AB 48,482.64 45,250.72 47,556.52 47,096.63 1664.32
VEGF 149.80 124.93 178.06 150.93 26.58
TGF-b1 65,876.29 66,978.92 91,598.06 74,817.76 14,542.62
huPL Z human platelet lysate; IGF-1 Z insulin-like growth factor-1; PDGF Z platelet-derived growth factor; TGF-b1 Z transforming
growth factor-b1; VEGF Z vascular endothelial growth factor.
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culture conditions were also consistently positive for CD73
and CD105, which are known to be expressed in MSCs (Table
3 and Figure 1). The expression of surface marker did not
differ between the different cell culture conditions.
Isolation and expansion of WJ-MSC
The WJ-MSCs were isolated for the proliferation assay. WJ-
MSCs were then cultured in a medium supplemented with
huPLeABO and FBS. Approximately 3 weeks after cultiva-
tion, fibroblast-like adherent cells migrated from the tissue
fragments. Microscopic analysis confirmed that both FBS-Table 3 Surface marker expression of WJ-MSCs cultured
with either FBS or huPL-ABO as analyzed by flow cytometry
at P4 and P8, n Z 3(mean percentage standard
deviation).
Surface
marker
FBS huPL-ABO
P4 P8 P4 P8
CD73 97.4 0.2 96.4 0.5 99.0 0.1 97.4 2.3
CD105 95.8 0.8 93.2 3.9 97.2 2.0 97.8 1.6
HLA-DR 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
CD14 1.2 1.0 1.3 1.1 1.3 1.1 1.4 1.5
CD19 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0
CD34 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
CD45 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
FBS Z fetal bovine serum; huPL Z human platelet lysate;
P4 Z Passage 4; P8 Z Passage 8; WJ-MSCs Z Wharton’s jelly-
derived mesenchymal stem cells.and huPLeABO-supplemented cells shared similar
morphology and density (Figure 2). At Passage 4 (P4), WJ-
MSCs cultured in all culture conditions also displayed a
fibroblast-like morphology (Figure 2). However, cells
cultured with huPLeABO appeared thinner, longer, and had
higher density compared with FBS-supplemented cells,
which resulted in higher cell number harvested from the
same surface area.
The optimal concentration of huPLeABO in the culture
medium was determined by culturing WJ-MSCs with various
concentrations of huPLeABO, and the PDT was calculated.
The optimal concentrations of huPLeABO in the culture
medium were 0.250 mg/mL and 0.125 mg/mL (Figure 3).
Because of insignificant differences between the concen-
trations in terms of WJ-MSCs PDT, 0.125 mg/mL was used as
the concentration of huPLeABO in all comparisons between
FBS and huPLeABO. PDT was calculated from P1 to P8 to
compare the effect of the two supplements on the prolif-
erative capacity of WJ-MSCs. The PDT was lower for WJ-
MSCs cultured in huPLeABO than in FBS, but significant
difference was observed only for P8 (p < 0.05; Figure 4).
The PDT of WJ-MSCs cultured in huPLeABO supplementa-
tion was more stable and less prone to fluctuations through
passages compared with those cultured in FBS supplemen-
tation. The high and stable cell proliferation rate of WJ-
MSCs in the huPLeABO-supplemented culture medium
resulted in higher cumulative cell number compared with
those cultured in the FBS-supplemented medium (Table 4).
[fx2]To study the optimal proliferation period closely,
proliferation assay of WJ-MSCs (n Z 5) for all culture con-
ditions was carried out at P4 (Figure 5). Cells were seeded
at the same density of 2  102 cells/cm2. Starting on Day 3,
cell numbers were counted and compared on each day with
Day 9. Proliferation kinetics of the growth curve showed a
Figure 1 Representation of flow cytometry measurement comparison results on CD105, CD73, CD14, CD19, CD34, CD45, and HLA-
II marker at (A) Passage 4 (P4) and (B) Passage 8 (P8) supplemented with fetal bovine serum (FBS) and human platelet lysate (huPL).
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Figure 1 (continued).
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Figure 2 Morphology of Wharton’s jelly-derived mesenchymal stem cells from one representative donor at Passage 4 (P4) and
Passage 8 (P8) in cultures supplemented with fetal bovine serum (FBS) and human platelet lysateeABO (huPLeABO). Magnification
100.
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Figure 4 Population doubling time of Wharton’s jelly-
derived mesenchymal stem cells supplemented with
0.125 mg/mL human platelet lysateeABO (huPLeABO) and 20%
fetal bovine serum (FBS) for Passage 1 (P1) through Passage 8
(P8). Each column represents the mean  standard error of
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tures starting on Day 5, which reached significant differ-
ence (p < 0.05) on Day 7, compared with those in the FBS-
supplemented cultures. Cultures with huPLeABO supple-
mentation reached a final cell count of 8.5  105 7.4 
104 on Day 7. In comparison, those with FBS supplementa-
tion reached a final cell count of 4.7  105 8.7  104 on
the same day. Both huPLeABO- and FBS-supplemented
cultures experienced a decrease in cell number on Day 9,
as they had already reached a postconfluence period on Day
7 or Day 8. The proliferation of these cells might be even
higher if a lower seeding density and a larger growth area
were used. The PDT of WJ-MSCs cultured with huPL also
showed more stability and less increase through passages
compared with those cultured with FBS. The high and sta-
ble cell proliferation rate of WJ-MSCs in the huPL-0
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Figure 3 Population doubling time of Wharton’s jelly-
derived mesenchymal stem cells supplemented with
0.250 mg/mL, 0.125 mg/mL, 0.063 mg/mL, and 0.031 mg/mL
human platelet lysateeABO. Each column represents the
mean  standard error of three independent experiments (*
p < 0.05).
three independent experiments (* p < 0.05).
Table 4 Cumulative cell number of WJ-MSCs cultured
with FBS and huPL-ABO from P1 through P8.
Passage FBS huPL-ABO
1 1.95  106 2.85  106
2 1.08  107 1.59  107
3 6.40  107 2.15  108
4 3.60  108 2.96  109
5 2.40  109 3.76  1010
6 1.72  1010 4.46  1011
7 1.12  1011 4.37  1012
8 5.96  1011 4.73  1013
FBS Z fetal bovine serum; huPL Z human platelet lysate;
P4 Z Passage 4; P8 Z Passage 8; WJ-MSCs Z Wharton’s jelly-
derived mesenchymal stem cells.
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Figure 5 Growth curve assessing the proliferation kinetics of
Wharton’s jelly-derived mesenchymal stem cells in 20% fetal
bovine serum (FBS) and 0.125 mg/mL human platelet lysate-
eABO (huPLeABO) on Day 3, Day 5, Day 7, and Day 9. (nZ 5).
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tive cell number compared with the same cells cultured in
the FBS-supplemented medium (Table 4).
Multilineage differentiation capacity of WJ-MSCs
The differentiation capacities of WJ-MSCs cultured in MEM
alpha supplemented with FBS and huPLeABO were evalu-
ated by culturing WJ-MSCs in the differentiation medium
(chondrogenic, osteogenic, and adipogenic lineages). After
culturing for approximately 7 days, the morphology of
chondrocytes, osteocytes, and adipocytes were studied.
Cell staining showed that WJ-MSCs cultured in both culture
conditions were able to differentiate into chondrocytes,
osteocytes, and adipocytes (Figure 6).
Discussion
The fact that huPL as an alternative supplement for culture
medium can trigger an explosive growth rate at earlier
passages makes it an attractive candidate for MSC expan-
sion in clinical settings, because for clinical applications
large numbers of MSCs are required in a short period for
transplantation into the human body.28 Platelet contains
many growth factors, which are stored in a-granules.
Inducing lysis in huPL by freezeethaw cycles has been
shown to release the growth factors from platelets, which
can stimulate cell proliferation efficiently both in vivo and
in vitro.22,29,30 The efficacy of huPL in promoting MSCs
expansion was investigated by evaluating its growth factors
concentration. This study showed that huPLeABO is rich in
PDGF-AB and TGF-b1; in addition, it contains VEGF and IGF-
1 in lower concentrations. Similar growth factors concen-
trations were reported by Mooren et al19 and Cho et al.13
Therefore, it can be concluded that the huPLeABO pro-
duction procedures carried out in this study did not affect
the effectiveness of platelets to release these growth fac-
tors.13,19 The concentration of all growth factors examined
in this study, except for IGF-1, showed high correlation with
protein concentrations of huPLeABO. Several studies have
shown that IGF-1 does not originate from platelets, but is
primarily excreted from the liver into the blood plasma,
which explains the low correlation of IGF-1 concentration
with protein concentration of huPLeABO in this study.13
The high correlation between growth factors and proteinconcentration of huPLeABO and the low variability of
growth factors concentration across batches make it
possible to create reproducible growth factors concentra-
tions in the culture medium supplemented with huPLeABO
from different batches. According to the study results, the
best concentration of huPLeABO in the culture medium was
0.125 mg/mL.
The study further showed that huPLeABO acts as a
growth-promoting factor in MSCs cultures. Cell culture
media supplemented with huPLeABO gave a higher prolif-
eration rate compared with those supplemented with FBS,
especially at late passages. In addition, the medium sup-
plemented with huPLeABO also had lower PDT and higher
cumulative cell number. Growth factors released by
platelets in huPLeABO are effective to stimulate prolifer-
ation of WJ-MSCs in vitro. This result can be concluded
from the growth curve of huPLeABO-cultured WJ-MSCs,
which showed more explosive growth starting from Day 3
compared with FBS-cultured WJ-MSCs, subsequently
resulting in higher cell number. Various studies using
exogenous growth factors, either alone or in combination,
have reported that basic fibroblast growth factor, TGF-b1,
IGF-1, and PDGFs are key factors involved in supporting the
expansion of MSCs ex vivo and maintaining their multi-
lineage potential for further differentiation.31e34 TGF-b1 is
involved in proliferation, differentiation, and migration of
MSCs, along with PDGF-AB, which acts as a powerful
mitogen. VEGF is involved in angiogenesis and wound
healing, whereas IGF-1 is important in controlling cell
apoptosis.20 All the growth factors in huPLeABO play a very
important role in maintaining WJ-MSCs proliferation, and in
this study all of the growth factors were effectively
extracted from the platelets in PRP by the freezeethaw
method. Therefore, the freezeethaw method is preferable
for production of huPLeABO owing to its high efficiency and
safety in releasing growth factors from PRP for clinical
applications. The method also does not require any addi-
tional substances that might induce an immunologic reac-
tion, and thus it is safe to administer WJ-MSCs grown in
huPLeABO for patients.
To ensure that the characteristics of MSCs are still pre-
served in the huPLeABO-cultured WJ-MSCs, we performed
immunophenotyping and differentiation capacity assays,
and the results were compared with those cultured in FBS.
Results of immunophenotyping and differentiation analyses
revealed that there are no significant differences between
WJ-MSCs cultured in the medium supplemented with
huPLeABO and those in the medium supplemented with
FBS. Both cell populations expressed specific MSCs markers
CD73 and CD105 (>95%), and lacked expression of CD34,
CD45, CD19, and HLA-DR (<2%). MSCs display a variety of
cell surface antigens that may vary according to the isola-
tion and expansion method. MSCs usually express CD73,
CD90, and CD105 and lack expression of major histocom-
patibility complex class II surface molecules and endothe-
lial CD31 and hematopietic-specific antigens (CD34, CD45,
and CD14).23,25,35 The production of MSCs was extremely
donor dependent for all culture conditions tested and could
be related to the WJ-MSCs isolation technique. Thus, it is
essential to eliminate non-MSCs and contaminated cells
before clinical application. Differentiation analysis
revealed that WJ-MSCs in both culture conditions were able
Differentiatioan 
WJ-MSCs
Treatment
FBS huPL
Adipogenic
Chondrogenic
Osteogenic
100 μm 100 μm
100 μm 200 μm
250 μm250 μm
Figure 6 Cell staining for Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) cultured with supplementation of fetal
bovine serum (FBS) and human platelet lysateeABO (huPLeABO) after incubation in the adipogenic, chondrogenic, and osteogenic
differentiation medium for 7 days. Magnification 100.
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adipogenic, chondrogenic, and osteogenic, with no signifi-
cant difference. Some studies have shown that a combi-
nation of growth factors in huPL inhibits the osteogenic
lineage and stimulates chondrogenic differentiation in
MSCs.10,13,15,30 However, Ben Azouna et al34 revealed that
the inhibitory effect of huPL on chondrogenic differentia-
tion of MSCs had no impact on the real multipotency of
MSCs, because they were able to fully differentiate further
toward the chondrogenic lineage. The inhibitory effect only
caused the MSCs to preserve their stemness and minimized
the risk of these cells entering senescence and trans-
formation, which can be of particular interest in clinical
applications.29,30 However, the concentration of huPL in
the culture medium needs to be assessed thoroughly,
because even a slight change in the amount of growth
factors in the culture medium could lead to variation in
results.35
For clinical applications, the proposed culture condi-
tions using huPLeABO appeared to be more advantageous
than using FBS. It can replace FBS for safe propagation of
functional MSCs, which thus avoids the risk of transmission
of bovine pathogen or immunogen, such as bovine serum
albumin and bovine apolipoprotein B-100, during their
culture for cell therapy.2 It is further recommended to
produce huPLeABO by matching platelets of blood group O
with plasma of blood group AB as performed in this study toavoid possible influences of ABH antigens and iso-
agglutinins.36 MSCs expanded using an autologous platelet
lysate technique show no evidence of malignant trans-
formation in vivo, following implantation of MSCs.37,38
In conclusion, our study shows that huPLeABO produced
by the freezeethaw method is able to enhance the WJ-MSCs
proliferation rate constantly and decrease the time
required to reach confluence compared with the FBS culture
condition. huPLeABO can replace FBS for safe propagation
of functional MSCs, thereby avoiding the risk of bovine
pathogen or immunogenic transmission, as well as the in-
fluence of ABH antigens and isoagglutinins, during their
culture for cell therapy. Although still not serum free, we
established an efficient and complete xeno-free protocol
for propagation of human WJ-MSCs. We propose that the
humanized system developed in this study for MSCs expan-
sion could be translated into a clinical expansion protocol.
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